» Articles » PMID: 17391432

Structure-function Relationships in Alpha-galactosidase A

Overview
Journal Acta Paediatr
Specialty Pediatrics
Date 2007 Mar 30
PMID 17391432
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: With recent interest in the molecular mechanisms responsible for Fabry disease, the number of known mutations in the GLA gene which encodes alpha-galactosidase A has expanded considerably. Combining a large database of Fabry disease-causing mutations with the recently determined crystal structure of human alpha-galactosidase A allows for a new understanding of the atomic defects in the protein responsible for Fabry disease. We have conducted a systematic survey of the known Fabry disease-causing mutations and analyzed the mutations in the context of the alpha-galactosidase A structure. We have applied quantitative methods for identifying the plausible effect of each mutation on the alpha-galactosidase A protein. We present the analysis of 331 different defects in the GLA gene leading to non-native proteins in patients with Fabry disease. These mutations include 278 missense mutations, 49 nonsense mutations, and four single amino acid deletions.

Conclusion: Over half of the residues in the protein have been found to have changes in patients with Fabry disease. Most of these genetic mutations lead to disruption of the hydrophobic core of the protein, thus Fabry disease is primarily a disease of protein-folding. Further understanding of alpha-galactosidase A, one of the best studied members of the lysosomal storage disease family, will lead to increased understanding of other lysosomal storage diseases and other protein-folding diseases.

Citing Articles

Phenotypic Expression and Outcomes in Patients with the p.Arg301Gln Variant in Anderson-Fabry Disease.

Blanco R, Rico-Ramirez Y, Hermida-Ameijeiras A, Abdullah I, Lau K, Alvarez-Rubio J Int J Mol Sci. 2024; 25(8).

PMID: 38673884 PMC: 11050256. DOI: 10.3390/ijms25084299.


Mechanistic Insights into Dibasic Iminosugars as pH-Selective Pharmacological Chaperones to Stabilize Human α-Galactosidase.

Li H, Lin H, Chang S, Chiu Y, Hou C, Ko T JACS Au. 2024; 4(3):908-918.

PMID: 38559739 PMC: 10976572. DOI: 10.1021/jacsau.3c00684.


What should rheumatologists know about Gaucher disease and Fabry disease? Connecting the dots for an overview.

Cordeiro R, Neto N, Mayrink Giardini H Adv Rheumatol. 2024; 64(1):22.

PMID: 38520029 DOI: 10.1186/s42358-024-00362-2.


Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.

Laffer B, Lenders M, Ehlers-Jeske E, Heidenreich K, Brand E, Kohl J Front Immunol. 2024; 15:1307558.

PMID: 38304433 PMC: 10830671. DOI: 10.3389/fimmu.2024.1307558.


Newborn Screening for Fabry Disease: Current Status of Knowledge.

Gragnaniello V, Burlina A, Commone A, Gueraldi D, Puma A, Porcu E Int J Neonatal Screen. 2023; 9(2).

PMID: 37367212 PMC: 10299185. DOI: 10.3390/ijns9020031.


References
1.
Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M . An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995; 333(5):288-93. DOI: 10.1056/NEJM199508033330504. View

2.
Madsen K, Hasholt L, Sorensen S, Fermer M, Dahl N . Two novel mutations (L32P) and (G85N) among five different missense mutations in six Danish families with Fabry's disease. Hum Mutat. 1995; 5(3):277-8. DOI: 10.1002/humu.1380050316. View

3.
Novo F, Kruszewski A, Macdermot K, Goldspink G, Gorecki D . Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion. Nucleic Acids Res. 1995; 23(14):2636-40. PMC: 307086. DOI: 10.1093/nar/23.14.2636. View

4.
Bairoch A, Apweiler R . The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 1999; 28(1):45-8. PMC: 102476. DOI: 10.1093/nar/28.1.45. View

5.
Rosenberg K, Schiffmann R, Kaneski C, Brady R, Sorensen S, Hasholt L . Five novel mutations in fourteen patients with Fabry Disease. Hum Mutat. 2000; 15(2):207-8. DOI: 10.1002/(SICI)1098-1004(200002)15:2<207::AID-HUMU16>3.0.CO;2-C. View